The growth factor receptor c-kit (CD117) is expressed in immature T-cells and in some advanced forms of mycosis fungoides. c-kit gene mutation results in unrestricted neoplastic proliferation. We aimed to detect by PCR the most frequent exon mutations in seventeen plaque-stage MF patients, in their perilesional skin and in healthy skin donors. We secondarily evaluated CD117 expression by immunohistochemistry in plaque-stage and tumor-stage MF. We detected no mutation in c-kit gene and low CD117 expression was confirmed on atypical cells in one patient. Complete c-kit exon and intron sequences should be assessed and more sensitive sequencing method could be also applied.
Mycosis fungoides (MF) is the most common type of primary cutaneous T-cell lymphoma (CTCL)
In particular, mutations in exons 9, 11, 13 and 17 activate c-kit constitutively, leading to an unrestricted tumor cell proliferation. Although Brauns et al. described CD117 expression in 27% MF, 50%
MF with transformation to a large T-cell lymphoma and 60% Sézary syndrome, so far there are no publications related to c-kit gene mutations in MF. [4] [5] [6] The purpose of this study was to assess the presence of c-kit gene mutations in exons 9, 11, 13 and 17 in plaque-stage ES-MF skin, and in apparently normal perilesional skin and healthy skin samples as control. Our secondary objective was to assess the expression of CD117 by immunohistochemistry (IHC) on those plaque-stage ES-MF patients.
We conducted a prospective case-control study at "Hospi- vanced-stage MF and Sézary syndrome could be related to a worse outcome and a lower survival. In our study, CD117 stained with low intensity for atypical T-cells in an 85-year-old type II skin phototype male with ES-MF. It is also remarkable that this patient developed ulcerated tumors months after concluding the study (Figure 1) . It is well known that atypical T-cells in MF expand in a polyclonal fashion, and consequently, not every clone would express the same mutations. Furthermore, it is important to remark the fact that Sanger sequencing has a low sensitivity threshold when assessing variant detection status on heterogeneous tumor samples. Sanger method is only capable of detecting mutations when the minor alleles are higher than 20%. [8] [9] [10] As a result of our research, we do not recommend that c-kit gene mutations in exons 9, 11, 13 and 17 should be analyzed by PCR as routine in plaque-stage ES-MF. A whole gene sequencing would provide a better understanding of the phenotype changes and the inconstant re-expression of CD117 in atypical T-cells on advanced-stage MF. q
No detection of c-kit gene mutations in exons 9, 11, 
